216 related articles for article (PubMed ID: 35705458)
21. Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial.
Macarulla T; Blanc JF; Wang-Gillam A; Chen LT; Siveke JT; Mirakhur B; Chen J; de Jong FA
J Geriatr Oncol; 2019 May; 10(3):427-435. PubMed ID: 30842038
[TBL] [Abstract][Full Text] [Related]
22. Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second-line treatment regimen for unresectable pancreatic cancer: A real-world analysis.
Tezuka S; Ueno M; Oishi R; Nagashima S; Sano Y; Kawano K; Tanaka S; Fukushima T; Asama H; Konno N; Kobayashi S; Morimoto M; Maeda S
Cancer Med; 2022 Feb; 11(4):1088-1098. PubMed ID: 34953056
[TBL] [Abstract][Full Text] [Related]
23. Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
Vogel A; Ciardiello F; Hubner RA; Blanc JF; Carrato A; Yang Y; Patel DA; Ektare V; de Jong FA; Gill S
Cancer Treat Rev; 2016 Nov; 50():142-147. PubMed ID: 27676174
[TBL] [Abstract][Full Text] [Related]
24. Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer.
Otsu T; Inokawa Y; Takami H; Hayashi M; Kurimoto K; Tanaka N; Tanaka H; Shimizu D; Hattori N; Kanda M; Tanaka C; Nakayama G; Kodera Y
Anticancer Res; 2022 Aug; 42(8):3889-3894. PubMed ID: 35896232
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy.
Bang K; Cheon J; Jeong JH; Im HS; Kim KP; Ryoo BY; Yoo C
Ther Adv Med Oncol; 2021; 13():17588359211003053. PubMed ID: 33796153
[TBL] [Abstract][Full Text] [Related]
26. Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer.
Hino K; Nishina T; Numata Y; Asagi A; Inoue T; Yoshimatsu M; Sakaguchi C; Nakasya A; Nishide N; Kajiwara T; Terao T; Nadano S; Marui K; Okujima Y; Kokubu M; Imamura Y; Kanemitsu K; Koizumi M; Kumagi T; Hiasa Y; Hyodo I
Intern Med; 2022; 61(15):2255-2261. PubMed ID: 35908959
[TBL] [Abstract][Full Text] [Related]
27. Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study.
Gupta A; De Jesus-Acosta A; Zheng L; Lee V; Kamel I; Le D; Pishvaian M; Laheru D
Front Oncol; 2023; 13():1250136. PubMed ID: 37700832
[TBL] [Abstract][Full Text] [Related]
28. Is There Room for Liposomal Irinotecan in Biliary Tract Cancer? A Meta-analysis of Randomised Trials.
Merz V; Messina C; Zecchetto C; Quinzii A; Frisinghelli M; Trentin C; Salati M; Caffo O; Melisi D
Clin Oncol (R Coll Radiol); 2024 Feb; 36(2):87-97. PubMed ID: 38129199
[TBL] [Abstract][Full Text] [Related]
29. 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice.
Yamai T; Ikezawa K; Kawamoto Y; Hirao T; Higashi S; Daiku K; Maeda S; Abe Y; Urabe M; Kai Y; Takada R; Nakabori T; Uehara H; Ohkawa K
Curr Oncol; 2022 Apr; 29(4):2644-2649. PubMed ID: 35448190
[TBL] [Abstract][Full Text] [Related]
30. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.
Hubner RA; Cubillo A; Blanc JF; Melisi D; Von Hoff DD; Wang-Gillam A; Chen LT; Becker C; Mamlouk K; Belanger B; Yang Y; de Jong FA; Siveke JT
Eur J Cancer; 2019 Jan; 106():24-33. PubMed ID: 30458340
[TBL] [Abstract][Full Text] [Related]
31. A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic adenocarcinoma.
Chun JW; Woo SM; Lee SH; Choi JH; Park N; Kim JS; Cho IR; Paik WH; Lee WJ; Ryu JK; Kim YT
Ther Adv Med Oncol; 2022; 14():17588359221119539. PubMed ID: 36062047
[TBL] [Abstract][Full Text] [Related]
32. A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid.
Kieler M; Unseld M; Bianconi D; Scheithauer W; Prager GW
Ther Adv Med Oncol; 2019; 11():1758835919853196. PubMed ID: 31360237
[TBL] [Abstract][Full Text] [Related]
33. Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
Kim G; Cockrum P; Surinach A; Wang S; Wainberg Z
Curr Med Res Opin; 2022 Aug; 38(8):1295-1303. PubMed ID: 35354375
[TBL] [Abstract][Full Text] [Related]
34. A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium.
Verbruggen L; Verheggen L; Vanhoutte G; Loly C; Lybaert W; Borbath I; Vergauwe P; Hendrickx K; Debeuckelaere C; de Haar-Holleman A; Van Laethem JL; Peeters M
Ther Adv Med Oncol; 2023; 15():17588359231181500. PubMed ID: 37600936
[TBL] [Abstract][Full Text] [Related]
35. A case of pathological complete response with liposomal irinotecan + 5-FU/LV for unresectable locally advanced pancreatic cancer.
Kikuchi K; Umemura A; Nitta H; Katagiri H; Nishiya M; Uesugi N; Sugai T; Imanari K; Sasaki A
Surg Case Rep; 2022 Oct; 8(1):192. PubMed ID: 36205833
[TBL] [Abstract][Full Text] [Related]
36. Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience.
Yu HY; Lee CY; Lin LG; Chao Y; Li CP
J Chin Med Assoc; 2022 Jan; 85(1):42-50. PubMed ID: 34759212
[TBL] [Abstract][Full Text] [Related]
37. Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin.
Chiu TJ; Yang SH; Chiu SC; Hsueh SW; Chiang NJ; Li CP; Bai LY; Cheng FM; Chuang SC; Shan YS; Chan DC; Chen LT; Yen CJ; Peng CM; Su YY; Chen YY; Chen JS; Chou WC
J Hepatobiliary Pancreat Sci; 2022 Jun; 29(6):670-681. PubMed ID: 35182031
[TBL] [Abstract][Full Text] [Related]
38. FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study.
Kobayashi S; Tezuka S; Yamachika Y; Tsunoda S; Nagashima S; Tozuka Y; Fukushima T; Morimoto M; Ueno M; Furuse J; Maeda S
BMC Cancer; 2023 Feb; 23(1):177. PubMed ID: 36809997
[TBL] [Abstract][Full Text] [Related]
39. Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.
Pelzer U; Blanc JF; Melisi D; Cubillo A; Von Hoff DD; Wang-Gillam A; Chen LT; Siveke JT; Wan Y; Solem CT; Botteman MF; Yang Y; de Jong FA; Hubner RA
Br J Cancer; 2017 May; 116(10):1247-1253. PubMed ID: 28350787
[TBL] [Abstract][Full Text] [Related]
40. A Retrospective Study Investigating the Safety and Efficacy of Nanoliposomal Irinotecan in Elderly Patients with Unresectable Pancreatic Cancer.
Ikoma T; Matsumoto T; Boku S; Yasuda T; Masuda M; Ito T; Nakamaru K; Yamaki S; Nakayama S; Hashimoto D; Yamamoto T; Shibata N; Ikeura T; Naganuma M; Satoi S; Kurata T
J Clin Med; 2023 May; 12(10):. PubMed ID: 37240585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
